Home > Insider Trading > Filing (0001209191-20-059404)

Filing Details

Accession Number:: 0001209191-20-059404
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-11-19 16:38:21
Reporting Period:: 2020-11-17

Accepted Time:: 2020-11-19 16:38:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1664710	Keros Therapeutics Inc.	KROS	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1726029	L.p. Iv (Cayman) Pontifax	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No
1726030	L.p. Iv (China) Pontifax	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No
1726039	Pontifax (Israel) Iv, L.p.	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No
1726334	Ltd. (2015) G.p. 4 Management Pontifax	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No
1793769	L.p. Fund Stage Late Pontifax	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No
1793770	Ltd. Gp Stage Late Pontifax	14 Shenkar Street, Beit Ofek Herzliya Pituach L3 46140	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-11-17	26,634	$50.00	2,288,151	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-11-17	12,966	$50.00	1,122,768	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-11-17	14,400	$50.00	1,228,326	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-11-17	6,000	$50.00	155,262	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.
Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.